Atracurium Besylate

Generic Name: Atracurium Besylate
Brand Name: -
Dosage Form: Injection 50mg/5ml
Pharmacological Category: Nondepolarizing skeletal muscle relaxant
Therapeutic Category: Antimyasthenics, Muscle Relaxants
Pregnancy Category: C

Pharmacology

Antagonize the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate

Pharmacokinetics:

The ED95 has averaged 0.23 mg/kg (0.11 to 0.26 mg/kg in various studies). An initial atracurium dose of 0.4 to 0.5 mg/kg generally produces maximum neuromuscular block within 3 to 5 minutes of injection, with good or excellent intubation conditions within 2 to 2.5 minutes in most patients. Recovery from neuromuscular block (under balanced anesthesia) can be expected to begin approximately 20 to 35 minutes after injection. Under balanced anesthesia, recovery to 25% of control is achieved approximately 35 to 45 minutes after injection, and recovery is usually 95% complete approximately 60 to 70 minutes after injection. The neuromuscular blocking action of atracurium is enhanced in the presence of potent inhalation anesthetics. Isoflurane and enflurane increase the potency of atracurium and prolong neuromuscular block by approximately 35%; however, halothane’s potentiating effect (approximately 20%) is marginal.

After an initial dose of 0.4 to 0.5 mg/ maintenance dose (suggested maintenance dose is 0.08 kg under balanced anesthesia, the first to 0.10 mg/kg) is generally required within 20 to 45 minutes, and subsequent maintenance doses are usually required at approximately 15 to 25 minute intervals. The pharmacokinetics of atracurium in humans are essentially linear within the 0.3 to 0.6 mg/kg dose range. The elimination half-life is approximately 20 minutes. The duration of neuromuscular block produced by atracurium besylate does not correlate with plasma pseudocholinesterase levels and is not altered by the absence of renal function.

Indications:

Adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Contraindications:

• Patients known to have a hypersensitivity to it

Precautions:

• Request information from your patients about previous anaphylactic reactions to other neuromuscular blocking agents.
• inform your patients that severe anaphylactic reactions to neuromuscular blocking agents, including atracurium besylate have been reported.

Drug Interactions:

Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine.

If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered.

Side Effects:

Common side effects of atracurium:
Temporary Redness of Face and Neck

Infrequent side effects of atracurium:
High Blood Pressure
Slow Heartbeat
Abnormally Low Blood Pressure
Fast Heartbeat

Rare side effects of atracurium IV:
Problems with Circulation
A Spasm of the Larynx
Bronchospasm
Inflammation of Skin caused by an Allergy
Redness of Skin
Itching
Hives
Rash
Visible Water Retention
Blood Circulation Failure due to Serious Heart Condition
Life Threatening Allergic Reaction

Storage:

• Store below 30 C°
• Protect from light and freezing

Packing:

• Atracurium Injection 50mg/5ml:5 Ampoules/ Box

stdClass Object ( [nid] => 279 [type] => product [language] => en [uid] => 1 [status] => 1 [created] => 1373631629 [changed] => 1388741067 [comment] => 0 [promote] => 0 [moderate] => 0 [sticky] => 0 [tnid] => 104 [translate] => 0 [vid] => 279 [revision_uid] => 1 [title] => Atracurium Besylate [body] =>
Image: 
Brand Name: 

-

Dosage Form: 

Injection 50mg/5ml

Pharmacological Category: 

Nondepolarizing skeletal muscle relaxant

Therapeutic Category: 

Antimyasthenics, Muscle Relaxants

Pregnancy Category: 

C

Antagonize the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate

Pharmacokinetics: 

The ED95 has averaged 0.23 mg/kg (0.11 to 0.26 mg/kg in various studies). An initial atracurium dose of 0.4 to 0.5 mg/kg generally produces maximum neuromuscular block within 3 to 5 minutes of injection, with good or excellent intubation conditions within 2 to 2.5 minutes in most patients. Recovery from neuromuscular block (under balanced anesthesia) can be expected to begin approximately 20 to 35 minutes after injection. Under balanced anesthesia, recovery to 25% of control is achieved approximately 35 to 45 minutes after injection, and recovery is usually 95% complete approximately 60 to 70 minutes after injection. The neuromuscular blocking action of atracurium is enhanced in the presence of potent inhalation anesthetics. Isoflurane and enflurane increase the potency of atracurium and prolong neuromuscular block by approximately 35%; however, halothane’s potentiating effect (approximately 20%) is marginal.

After an initial dose of 0.4 to 0.5 mg/ maintenance dose (suggested maintenance dose is 0.08 kg under balanced anesthesia, the first to 0.10 mg/kg) is generally required within 20 to 45 minutes, and subsequent maintenance doses are usually required at approximately 15 to 25 minute intervals. The pharmacokinetics of atracurium in humans are essentially linear within the 0.3 to 0.6 mg/kg dose range. The elimination half-life is approximately 20 minutes. The duration of neuromuscular block produced by atracurium besylate does not correlate with plasma pseudocholinesterase levels and is not altered by the absence of renal function.

Indications: 

Adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Contraindications: 

• Patients known to have a hypersensitivity to it

Precautions: 

• Request information from your patients about previous anaphylactic reactions to other neuromuscular blocking agents.
• inform your patients that severe anaphylactic reactions to neuromuscular blocking agents, including atracurium besylate have been reported.

Drug Interactions: 

Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine.

If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered.

Side Effects: 

Common side effects of atracurium:
Temporary Redness of Face and Neck

Infrequent side effects of atracurium:
High Blood Pressure
Slow Heartbeat
Abnormally Low Blood Pressure
Fast Heartbeat

Rare side effects of atracurium IV:
Problems with Circulation
A Spasm of the Larynx
Bronchospasm
Inflammation of Skin caused by an Allergy
Redness of Skin
Itching
Hives
Rash
Visible Water Retention
Blood Circulation Failure due to Serious Heart Condition
Life Threatening Allergic Reaction

Storage: 

• Store below 30 C°
• Protect from light and freezing

Packing: 

• Atracurium Injection 50mg/5ml:5 Ampoules/ Box

[log] => [revision_timestamp] => 1388741067 [format] => 1 [name] => root [picture] => [data] => a:5:{s:29:"taxonomy_image_disable_images";i:0;s:20:"l10n_client_disabled";i:0;s:13:"form_build_id";s:48:"form-MBxN_vyi5HhAsg0I2XKWS7o1OdWz8gzblI4ECSrLqIU";s:18:"admin_compact_mode";b:1;s:7:"contact";i:0;} [path] => product/atracurium-besylate [field_one_image] => Array ( [0] => Array ( [fid] => 170 [uid] => 1 [filename] => atracurium_s.jpg [filepath] => sites/default/files/images/atracurium_s.jpg [filemime] => image/jpeg [filesize] => 72347 [status] => 1 [timestamp] => 1329486096 [list] => 1 [data] => Array ( [alt] => [title] => ) [i18nsync] => 1 [nid] => 279 [view] => ) ) [field_administration_and_dosage] => Array ( [0] => Array ( [value] => [format] => [safe] => [view] => ) ) [field_brand_name] => Array ( [0] => Array ( [value] => - [format] => 1 [safe] =>

-

[view] =>

-

) ) [field_contraindications] => Array ( [0] => Array ( [value] => • Patients known to have a hypersensitivity to it [format] => 1 [safe] =>

• Patients known to have a hypersensitivity to it

[view] =>

• Patients known to have a hypersensitivity to it

) ) [field_dosage_form] => Array ( [0] => Array ( [value] => Injection 50mg/5ml [format] => 1 [safe] =>

Injection 50mg/5ml

[view] =>

Injection 50mg/5ml

) ) [field_drug_interactions] => Array ( [0] => Array ( [value] => Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine. If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered. [format] => 1 [safe] =>

Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine.

If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered.

[view] =>

Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine.

If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered.

) ) [field_indications] => Array ( [0] => Array ( [value] => Adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. [format] => 1 [safe] =>

Adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

[view] =>

Adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

) ) [field_packing] => Array ( [0] => Array ( [value] => • Atracurium Injection 50mg/5ml:5 Ampoules/ Box [format] => 1 [safe] =>

• Atracurium Injection 50mg/5ml:5 Ampoules/ Box

[view] =>

• Atracurium Injection 50mg/5ml:5 Ampoules/ Box

) ) [field_pdf] => Array ( [0] => Array ( [fid] => 171 [uid] => 1 [filename] => atracurium.pdf [filepath] => sites/default/files/pdf/atracurium.pdf [filemime] => application/pdf [filesize] => 511067 [status] => 1 [timestamp] => 1329486214 [list] => 1 [data] => [i18nsync] => 1 [nid] => 279 [view] => ) ) [field_pharmacokinetics] => Array ( [0] => Array ( [value] => The ED95 has averaged 0.23 mg/kg (0.11 to 0.26 mg/kg in various studies). An initial atracurium dose of 0.4 to 0.5 mg/kg generally produces maximum neuromuscular block within 3 to 5 minutes of injection, with good or excellent intubation conditions within 2 to 2.5 minutes in most patients. Recovery from neuromuscular block (under balanced anesthesia) can be expected to begin approximately 20 to 35 minutes after injection. Under balanced anesthesia, recovery to 25% of control is achieved approximately 35 to 45 minutes after injection, and recovery is usually 95% complete approximately 60 to 70 minutes after injection. The neuromuscular blocking action of atracurium is enhanced in the presence of potent inhalation anesthetics. Isoflurane and enflurane increase the potency of atracurium and prolong neuromuscular block by approximately 35%; however, halothane’s potentiating effect (approximately 20%) is marginal. After an initial dose of 0.4 to 0.5 mg/ maintenance dose (suggested maintenance dose is 0.08 kg under balanced anesthesia, the first to 0.10 mg/kg) is generally required within 20 to 45 minutes, and subsequent maintenance doses are usually required at approximately 15 to 25 minute intervals. The pharmacokinetics of atracurium in humans are essentially linear within the 0.3 to 0.6 mg/kg dose range. The elimination half-life is approximately 20 minutes. The duration of neuromuscular block produced by atracurium besylate does not correlate with plasma pseudocholinesterase levels and is not altered by the absence of renal function. [format] => 1 [safe] =>

The ED95 has averaged 0.23 mg/kg (0.11 to 0.26 mg/kg in various studies). An initial atracurium dose of 0.4 to 0.5 mg/kg generally produces maximum neuromuscular block within 3 to 5 minutes of injection, with good or excellent intubation conditions within 2 to 2.5 minutes in most patients. Recovery from neuromuscular block (under balanced anesthesia) can be expected to begin approximately 20 to 35 minutes after injection. Under balanced anesthesia, recovery to 25% of control is achieved approximately 35 to 45 minutes after injection, and recovery is usually 95% complete approximately 60 to 70 minutes after injection. The neuromuscular blocking action of atracurium is enhanced in the presence of potent inhalation anesthetics. Isoflurane and enflurane increase the potency of atracurium and prolong neuromuscular block by approximately 35%; however, halothane’s potentiating effect (approximately 20%) is marginal.

After an initial dose of 0.4 to 0.5 mg/ maintenance dose (suggested maintenance dose is 0.08 kg under balanced anesthesia, the first to 0.10 mg/kg) is generally required within 20 to 45 minutes, and subsequent maintenance doses are usually required at approximately 15 to 25 minute intervals. The pharmacokinetics of atracurium in humans are essentially linear within the 0.3 to 0.6 mg/kg dose range. The elimination half-life is approximately 20 minutes. The duration of neuromuscular block produced by atracurium besylate does not correlate with plasma pseudocholinesterase levels and is not altered by the absence of renal function.

[view] =>

The ED95 has averaged 0.23 mg/kg (0.11 to 0.26 mg/kg in various studies). An initial atracurium dose of 0.4 to 0.5 mg/kg generally produces maximum neuromuscular block within 3 to 5 minutes of injection, with good or excellent intubation conditions within 2 to 2.5 minutes in most patients. Recovery from neuromuscular block (under balanced anesthesia) can be expected to begin approximately 20 to 35 minutes after injection. Under balanced anesthesia, recovery to 25% of control is achieved approximately 35 to 45 minutes after injection, and recovery is usually 95% complete approximately 60 to 70 minutes after injection. The neuromuscular blocking action of atracurium is enhanced in the presence of potent inhalation anesthetics. Isoflurane and enflurane increase the potency of atracurium and prolong neuromuscular block by approximately 35%; however, halothane’s potentiating effect (approximately 20%) is marginal.

After an initial dose of 0.4 to 0.5 mg/ maintenance dose (suggested maintenance dose is 0.08 kg under balanced anesthesia, the first to 0.10 mg/kg) is generally required within 20 to 45 minutes, and subsequent maintenance doses are usually required at approximately 15 to 25 minute intervals. The pharmacokinetics of atracurium in humans are essentially linear within the 0.3 to 0.6 mg/kg dose range. The elimination half-life is approximately 20 minutes. The duration of neuromuscular block produced by atracurium besylate does not correlate with plasma pseudocholinesterase levels and is not altered by the absence of renal function.

) ) [field_pharmacological_category] => Array ( [0] => Array ( [value] => Nondepolarizing skeletal muscle relaxant [format] => 1 [safe] =>

Nondepolarizing skeletal muscle relaxant

[view] =>

Nondepolarizing skeletal muscle relaxant

) ) [field_precautions] => Array ( [0] => Array ( [value] => • Request information from your patients about previous anaphylactic reactions to other neuromuscular blocking agents. • inform your patients that severe anaphylactic reactions to neuromuscular blocking agents, including atracurium besylate have been reported. [format] => 1 [safe] =>

• Request information from your patients about previous anaphylactic reactions to other neuromuscular blocking agents.
• inform your patients that severe anaphylactic reactions to neuromuscular blocking agents, including atracurium besylate have been reported.

[view] =>

• Request information from your patients about previous anaphylactic reactions to other neuromuscular blocking agents.
• inform your patients that severe anaphylactic reactions to neuromuscular blocking agents, including atracurium besylate have been reported.

) ) [field_pregnancy_category] => Array ( [0] => Array ( [value] => C [format] => 1 [safe] =>

C

[view] =>

C

) ) [field_references] => Array ( [0] => Array ( [value] => [format] => [safe] => [view] => ) ) [field_side_effects] => Array ( [0] => Array ( [value] => Common side effects of atracurium: Temporary Redness of Face and Neck Infrequent side effects of atracurium: High Blood Pressure Slow Heartbeat Abnormally Low Blood Pressure Fast Heartbeat Rare side effects of atracurium IV: Problems with Circulation A Spasm of the Larynx Bronchospasm Inflammation of Skin caused by an Allergy Redness of Skin Itching Hives Rash Visible Water Retention Blood Circulation Failure due to Serious Heart Condition Life Threatening Allergic Reaction [format] => 1 [safe] =>

Common side effects of atracurium:
Temporary Redness of Face and Neck

Infrequent side effects of atracurium:
High Blood Pressure
Slow Heartbeat
Abnormally Low Blood Pressure
Fast Heartbeat

Rare side effects of atracurium IV:
Problems with Circulation
A Spasm of the Larynx
Bronchospasm
Inflammation of Skin caused by an Allergy
Redness of Skin
Itching
Hives
Rash
Visible Water Retention
Blood Circulation Failure due to Serious Heart Condition
Life Threatening Allergic Reaction

[view] =>

Common side effects of atracurium:
Temporary Redness of Face and Neck

Infrequent side effects of atracurium:
High Blood Pressure
Slow Heartbeat
Abnormally Low Blood Pressure
Fast Heartbeat

Rare side effects of atracurium IV:
Problems with Circulation
A Spasm of the Larynx
Bronchospasm
Inflammation of Skin caused by an Allergy
Redness of Skin
Itching
Hives
Rash
Visible Water Retention
Blood Circulation Failure due to Serious Heart Condition
Life Threatening Allergic Reaction

) ) [field_storage] => Array ( [0] => Array ( [value] => • Store below 30 C° • Protect from light and freezing [format] => 1 [safe] =>

• Store below 30 C°
• Protect from light and freezing

[view] =>

• Store below 30 C°
• Protect from light and freezing

) ) [field_therapeutic_category] => Array ( [0] => Array ( [value] => Antimyasthenics, Muscle Relaxants [format] => 1 [safe] =>

Antimyasthenics, Muscle Relaxants

[view] =>

Antimyasthenics, Muscle Relaxants

) ) [field_related_products] => Array ( [0] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) [1] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) [2] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) ) [taxonomy] => Array ( [3] => stdClass Object ( [tid] => 3 [vid] => 1 [name] => Antimyasthenics ,Muscle Relaxants [description] => [weight] => 1 [language] => [trid] => 0 [v_weight_unused] => 0 ) ) [build_mode] => 0 [readmore] => [content] => Array ( [field_one_image] => Array ( [#type_name] => product [#context] => full [#field_name] => field_one_image [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => -3 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => image_plain [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_one_image [#weight] => 0 [#theme] => imagefield_formatter_image_plain [#item] => Array ( [fid] => 170 [uid] => 1 [filename] => atracurium_s.jpg [filepath] => sites/default/files/images/atracurium_s.jpg [filemime] => image/jpeg [filesize] => 72347 [status] => 1 [timestamp] => 1329486096 [list] => 1 [data] => Array ( [alt] => [title] => ) [i18nsync] => 1 [nid] => 279 [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] => ) [#title] => [#description] => [#children] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_one_image [#title] => Image [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] => [#printed] => 1 ) [#title] => [#description] => [#children] =>
Image: 
[#printed] => 1 ) [field_brand_name] => Array ( [#type_name] => product [#context] => full [#field_name] => field_brand_name [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => -2 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_brand_name [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => - [format] => 1 [safe] =>

-

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

-

) [#title] => [#description] => [#children] =>

-

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_brand_name [#title] => Brand Name [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

-

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Brand Name: 

-

[#printed] => 1 ) [field_dosage_form] => Array ( [#type_name] => product [#context] => full [#field_name] => field_dosage_form [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => -1 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_dosage_form [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Injection 50mg/5ml [format] => 1 [safe] =>

Injection 50mg/5ml

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Injection 50mg/5ml

) [#title] => [#description] => [#children] =>

Injection 50mg/5ml

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_dosage_form [#title] => Dosage Form [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Injection 50mg/5ml

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Dosage Form: 

Injection 50mg/5ml

[#printed] => 1 ) [#pre_render] => Array ( [0] => content_alter_extra_weights ) [field_pharmacological_category] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pharmacological_category [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 0 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pharmacological_category [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Nondepolarizing skeletal muscle relaxant [format] => 1 [safe] =>

Nondepolarizing skeletal muscle relaxant

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Nondepolarizing skeletal muscle relaxant

) [#title] => [#description] => [#children] =>

Nondepolarizing skeletal muscle relaxant

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pharmacological_category [#title] => Pharmacological Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Nondepolarizing skeletal muscle relaxant

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Pharmacological Category: 

Nondepolarizing skeletal muscle relaxant

[#printed] => 1 ) [#content_extra_fields] => Array ( [title] => Array ( [label] => Generic Name [description] => Node module form. [weight] => -5 ) [body_field] => Array ( [label] => Pharmacology [description] => Node module form. [weight] => 3 [view] => body ) [revision_information] => Array ( [label] => Revision information [description] => Node module form. [weight] => 18 ) [author] => Array ( [label] => Authoring information [description] => Node module form. [weight] => 19 ) [options] => Array ( [label] => Publishing options [description] => Node module form. [weight] => 20 ) [language] => Array ( [label] => Language [description] => Locale module form. [weight] => -4 ) [translation] => Array ( [label] => Translation settings [description] => Translation module form. [weight] => 21 ) [menu] => Array ( [label] => Menu settings [description] => Menu module form. [weight] => 17 ) [taxonomy] => Array ( [label] => Taxonomy [description] => Taxonomy module form. [weight] => -3 ) [path] => Array ( [label] => Path settings [description] => Path module form. [weight] => 16 ) [custom_breadcrumbs] => Array ( [label] => Custom Breadcrumbs [description] => Custom Breadcrumbs module form. [weight] => 30 ) ) [field_therapeutic_category] => Array ( [#type_name] => product [#context] => full [#field_name] => field_therapeutic_category [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 1 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_therapeutic_category [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Antimyasthenics, Muscle Relaxants [format] => 1 [safe] =>

Antimyasthenics, Muscle Relaxants

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Antimyasthenics, Muscle Relaxants

) [#title] => [#description] => [#children] =>

Antimyasthenics, Muscle Relaxants

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_therapeutic_category [#title] => Therapeutic Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Antimyasthenics, Muscle Relaxants

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Therapeutic Category: 

Antimyasthenics, Muscle Relaxants

[#printed] => 1 ) [field_pregnancy_category] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pregnancy_category [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 2 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pregnancy_category [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => C [format] => 1 [safe] =>

C

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

C

) [#title] => [#description] => [#children] =>

C

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pregnancy_category [#title] => Pregnancy Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

C

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Pregnancy Category: 

C

[#printed] => 1 ) [body] => Array ( [#weight] => 3 [#value] =>

Antagonize the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate

[#title] => [#description] => [#printed] => 1 ) [field_pharmacokinetics] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pharmacokinetics [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 4 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pharmacokinetics [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => The ED95 has averaged 0.23 mg/kg (0.11 to 0.26 mg/kg in various studies). An initial atracurium dose of 0.4 to 0.5 mg/kg generally produces maximum neuromuscular block within 3 to 5 minutes of injection, with good or excellent intubation conditions within 2 to 2.5 minutes in most patients. Recovery from neuromuscular block (under balanced anesthesia) can be expected to begin approximately 20 to 35 minutes after injection. Under balanced anesthesia, recovery to 25% of control is achieved approximately 35 to 45 minutes after injection, and recovery is usually 95% complete approximately 60 to 70 minutes after injection. The neuromuscular blocking action of atracurium is enhanced in the presence of potent inhalation anesthetics. Isoflurane and enflurane increase the potency of atracurium and prolong neuromuscular block by approximately 35%; however, halothane’s potentiating effect (approximately 20%) is marginal. After an initial dose of 0.4 to 0.5 mg/ maintenance dose (suggested maintenance dose is 0.08 kg under balanced anesthesia, the first to 0.10 mg/kg) is generally required within 20 to 45 minutes, and subsequent maintenance doses are usually required at approximately 15 to 25 minute intervals. The pharmacokinetics of atracurium in humans are essentially linear within the 0.3 to 0.6 mg/kg dose range. The elimination half-life is approximately 20 minutes. The duration of neuromuscular block produced by atracurium besylate does not correlate with plasma pseudocholinesterase levels and is not altered by the absence of renal function. [format] => 1 [safe] =>

The ED95 has averaged 0.23 mg/kg (0.11 to 0.26 mg/kg in various studies). An initial atracurium dose of 0.4 to 0.5 mg/kg generally produces maximum neuromuscular block within 3 to 5 minutes of injection, with good or excellent intubation conditions within 2 to 2.5 minutes in most patients. Recovery from neuromuscular block (under balanced anesthesia) can be expected to begin approximately 20 to 35 minutes after injection. Under balanced anesthesia, recovery to 25% of control is achieved approximately 35 to 45 minutes after injection, and recovery is usually 95% complete approximately 60 to 70 minutes after injection. The neuromuscular blocking action of atracurium is enhanced in the presence of potent inhalation anesthetics. Isoflurane and enflurane increase the potency of atracurium and prolong neuromuscular block by approximately 35%; however, halothane’s potentiating effect (approximately 20%) is marginal.

After an initial dose of 0.4 to 0.5 mg/ maintenance dose (suggested maintenance dose is 0.08 kg under balanced anesthesia, the first to 0.10 mg/kg) is generally required within 20 to 45 minutes, and subsequent maintenance doses are usually required at approximately 15 to 25 minute intervals. The pharmacokinetics of atracurium in humans are essentially linear within the 0.3 to 0.6 mg/kg dose range. The elimination half-life is approximately 20 minutes. The duration of neuromuscular block produced by atracurium besylate does not correlate with plasma pseudocholinesterase levels and is not altered by the absence of renal function.

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

The ED95 has averaged 0.23 mg/kg (0.11 to 0.26 mg/kg in various studies). An initial atracurium dose of 0.4 to 0.5 mg/kg generally produces maximum neuromuscular block within 3 to 5 minutes of injection, with good or excellent intubation conditions within 2 to 2.5 minutes in most patients. Recovery from neuromuscular block (under balanced anesthesia) can be expected to begin approximately 20 to 35 minutes after injection. Under balanced anesthesia, recovery to 25% of control is achieved approximately 35 to 45 minutes after injection, and recovery is usually 95% complete approximately 60 to 70 minutes after injection. The neuromuscular blocking action of atracurium is enhanced in the presence of potent inhalation anesthetics. Isoflurane and enflurane increase the potency of atracurium and prolong neuromuscular block by approximately 35%; however, halothane’s potentiating effect (approximately 20%) is marginal.

After an initial dose of 0.4 to 0.5 mg/ maintenance dose (suggested maintenance dose is 0.08 kg under balanced anesthesia, the first to 0.10 mg/kg) is generally required within 20 to 45 minutes, and subsequent maintenance doses are usually required at approximately 15 to 25 minute intervals. The pharmacokinetics of atracurium in humans are essentially linear within the 0.3 to 0.6 mg/kg dose range. The elimination half-life is approximately 20 minutes. The duration of neuromuscular block produced by atracurium besylate does not correlate with plasma pseudocholinesterase levels and is not altered by the absence of renal function.

) [#title] => [#description] => [#children] =>

The ED95 has averaged 0.23 mg/kg (0.11 to 0.26 mg/kg in various studies). An initial atracurium dose of 0.4 to 0.5 mg/kg generally produces maximum neuromuscular block within 3 to 5 minutes of injection, with good or excellent intubation conditions within 2 to 2.5 minutes in most patients. Recovery from neuromuscular block (under balanced anesthesia) can be expected to begin approximately 20 to 35 minutes after injection. Under balanced anesthesia, recovery to 25% of control is achieved approximately 35 to 45 minutes after injection, and recovery is usually 95% complete approximately 60 to 70 minutes after injection. The neuromuscular blocking action of atracurium is enhanced in the presence of potent inhalation anesthetics. Isoflurane and enflurane increase the potency of atracurium and prolong neuromuscular block by approximately 35%; however, halothane’s potentiating effect (approximately 20%) is marginal.

After an initial dose of 0.4 to 0.5 mg/ maintenance dose (suggested maintenance dose is 0.08 kg under balanced anesthesia, the first to 0.10 mg/kg) is generally required within 20 to 45 minutes, and subsequent maintenance doses are usually required at approximately 15 to 25 minute intervals. The pharmacokinetics of atracurium in humans are essentially linear within the 0.3 to 0.6 mg/kg dose range. The elimination half-life is approximately 20 minutes. The duration of neuromuscular block produced by atracurium besylate does not correlate with plasma pseudocholinesterase levels and is not altered by the absence of renal function.

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pharmacokinetics [#title] => Pharmacokinetics [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

The ED95 has averaged 0.23 mg/kg (0.11 to 0.26 mg/kg in various studies). An initial atracurium dose of 0.4 to 0.5 mg/kg generally produces maximum neuromuscular block within 3 to 5 minutes of injection, with good or excellent intubation conditions within 2 to 2.5 minutes in most patients. Recovery from neuromuscular block (under balanced anesthesia) can be expected to begin approximately 20 to 35 minutes after injection. Under balanced anesthesia, recovery to 25% of control is achieved approximately 35 to 45 minutes after injection, and recovery is usually 95% complete approximately 60 to 70 minutes after injection. The neuromuscular blocking action of atracurium is enhanced in the presence of potent inhalation anesthetics. Isoflurane and enflurane increase the potency of atracurium and prolong neuromuscular block by approximately 35%; however, halothane’s potentiating effect (approximately 20%) is marginal.

After an initial dose of 0.4 to 0.5 mg/ maintenance dose (suggested maintenance dose is 0.08 kg under balanced anesthesia, the first to 0.10 mg/kg) is generally required within 20 to 45 minutes, and subsequent maintenance doses are usually required at approximately 15 to 25 minute intervals. The pharmacokinetics of atracurium in humans are essentially linear within the 0.3 to 0.6 mg/kg dose range. The elimination half-life is approximately 20 minutes. The duration of neuromuscular block produced by atracurium besylate does not correlate with plasma pseudocholinesterase levels and is not altered by the absence of renal function.

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Pharmacokinetics: 

The ED95 has averaged 0.23 mg/kg (0.11 to 0.26 mg/kg in various studies). An initial atracurium dose of 0.4 to 0.5 mg/kg generally produces maximum neuromuscular block within 3 to 5 minutes of injection, with good or excellent intubation conditions within 2 to 2.5 minutes in most patients. Recovery from neuromuscular block (under balanced anesthesia) can be expected to begin approximately 20 to 35 minutes after injection. Under balanced anesthesia, recovery to 25% of control is achieved approximately 35 to 45 minutes after injection, and recovery is usually 95% complete approximately 60 to 70 minutes after injection. The neuromuscular blocking action of atracurium is enhanced in the presence of potent inhalation anesthetics. Isoflurane and enflurane increase the potency of atracurium and prolong neuromuscular block by approximately 35%; however, halothane’s potentiating effect (approximately 20%) is marginal.

After an initial dose of 0.4 to 0.5 mg/ maintenance dose (suggested maintenance dose is 0.08 kg under balanced anesthesia, the first to 0.10 mg/kg) is generally required within 20 to 45 minutes, and subsequent maintenance doses are usually required at approximately 15 to 25 minute intervals. The pharmacokinetics of atracurium in humans are essentially linear within the 0.3 to 0.6 mg/kg dose range. The elimination half-life is approximately 20 minutes. The duration of neuromuscular block produced by atracurium besylate does not correlate with plasma pseudocholinesterase levels and is not altered by the absence of renal function.

[#printed] => 1 ) [field_indications] => Array ( [#type_name] => product [#context] => full [#field_name] => field_indications [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 5 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_indications [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. [format] => 1 [safe] =>

Adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

) [#title] => [#description] => [#children] =>

Adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_indications [#title] => Indications [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Indications: 

Adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

[#printed] => 1 ) [field_administration_and_dosage] => Array ( [#type_name] => product [#context] => full [#field_name] => field_administration_and_dosage [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 6 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_administration_and_dosage [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => [format] => [safe] => [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [#title] => [#description] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_administration_and_dosage [#title] => Administration and Dosage [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#printed] => 1 ) [#title] => [#description] => [#printed] => 1 ) [field_contraindications] => Array ( [#type_name] => product [#context] => full [#field_name] => field_contraindications [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 7 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_contraindications [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => • Patients known to have a hypersensitivity to it [format] => 1 [safe] =>

• Patients known to have a hypersensitivity to it

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

• Patients known to have a hypersensitivity to it

) [#title] => [#description] => [#children] =>

• Patients known to have a hypersensitivity to it

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_contraindications [#title] => Contraindications [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

• Patients known to have a hypersensitivity to it

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Contraindications: 

• Patients known to have a hypersensitivity to it

[#printed] => 1 ) [field_precautions] => Array ( [#type_name] => product [#context] => full [#field_name] => field_precautions [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 8 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_precautions [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => • Request information from your patients about previous anaphylactic reactions to other neuromuscular blocking agents. • inform your patients that severe anaphylactic reactions to neuromuscular blocking agents, including atracurium besylate have been reported. [format] => 1 [safe] =>

• Request information from your patients about previous anaphylactic reactions to other neuromuscular blocking agents.
• inform your patients that severe anaphylactic reactions to neuromuscular blocking agents, including atracurium besylate have been reported.

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

• Request information from your patients about previous anaphylactic reactions to other neuromuscular blocking agents.
• inform your patients that severe anaphylactic reactions to neuromuscular blocking agents, including atracurium besylate have been reported.

) [#title] => [#description] => [#children] =>

• Request information from your patients about previous anaphylactic reactions to other neuromuscular blocking agents.
• inform your patients that severe anaphylactic reactions to neuromuscular blocking agents, including atracurium besylate have been reported.

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_precautions [#title] => Precautions [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

• Request information from your patients about previous anaphylactic reactions to other neuromuscular blocking agents.
• inform your patients that severe anaphylactic reactions to neuromuscular blocking agents, including atracurium besylate have been reported.

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Precautions: 

• Request information from your patients about previous anaphylactic reactions to other neuromuscular blocking agents.
• inform your patients that severe anaphylactic reactions to neuromuscular blocking agents, including atracurium besylate have been reported.

[#printed] => 1 ) [field_drug_interactions] => Array ( [#type_name] => product [#context] => full [#field_name] => field_drug_interactions [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 9 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_drug_interactions [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine. If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered. [format] => 1 [safe] =>

Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine.

If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered.

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine.

If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered.

) [#title] => [#description] => [#children] =>

Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine.

If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered.

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_drug_interactions [#title] => Drug Interactions [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine.

If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered.

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Drug Interactions: 

Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine.

If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered.

[#printed] => 1 ) [field_side_effects] => Array ( [#type_name] => product [#context] => full [#field_name] => field_side_effects [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 10 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_side_effects [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Common side effects of atracurium: Temporary Redness of Face and Neck Infrequent side effects of atracurium: High Blood Pressure Slow Heartbeat Abnormally Low Blood Pressure Fast Heartbeat Rare side effects of atracurium IV: Problems with Circulation A Spasm of the Larynx Bronchospasm Inflammation of Skin caused by an Allergy Redness of Skin Itching Hives Rash Visible Water Retention Blood Circulation Failure due to Serious Heart Condition Life Threatening Allergic Reaction [format] => 1 [safe] =>

Common side effects of atracurium:
Temporary Redness of Face and Neck

Infrequent side effects of atracurium:
High Blood Pressure
Slow Heartbeat
Abnormally Low Blood Pressure
Fast Heartbeat

Rare side effects of atracurium IV:
Problems with Circulation
A Spasm of the Larynx
Bronchospasm
Inflammation of Skin caused by an Allergy
Redness of Skin
Itching
Hives
Rash
Visible Water Retention
Blood Circulation Failure due to Serious Heart Condition
Life Threatening Allergic Reaction

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Common side effects of atracurium:
Temporary Redness of Face and Neck

Infrequent side effects of atracurium:
High Blood Pressure
Slow Heartbeat
Abnormally Low Blood Pressure
Fast Heartbeat

Rare side effects of atracurium IV:
Problems with Circulation
A Spasm of the Larynx
Bronchospasm
Inflammation of Skin caused by an Allergy
Redness of Skin
Itching
Hives
Rash
Visible Water Retention
Blood Circulation Failure due to Serious Heart Condition
Life Threatening Allergic Reaction

) [#title] => [#description] => [#children] =>

Common side effects of atracurium:
Temporary Redness of Face and Neck

Infrequent side effects of atracurium:
High Blood Pressure
Slow Heartbeat
Abnormally Low Blood Pressure
Fast Heartbeat

Rare side effects of atracurium IV:
Problems with Circulation
A Spasm of the Larynx
Bronchospasm
Inflammation of Skin caused by an Allergy
Redness of Skin
Itching
Hives
Rash
Visible Water Retention
Blood Circulation Failure due to Serious Heart Condition
Life Threatening Allergic Reaction

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_side_effects [#title] => Side Effects [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Common side effects of atracurium:
Temporary Redness of Face and Neck

Infrequent side effects of atracurium:
High Blood Pressure
Slow Heartbeat
Abnormally Low Blood Pressure
Fast Heartbeat

Rare side effects of atracurium IV:
Problems with Circulation
A Spasm of the Larynx
Bronchospasm
Inflammation of Skin caused by an Allergy
Redness of Skin
Itching
Hives
Rash
Visible Water Retention
Blood Circulation Failure due to Serious Heart Condition
Life Threatening Allergic Reaction

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Side Effects: 

Common side effects of atracurium:
Temporary Redness of Face and Neck

Infrequent side effects of atracurium:
High Blood Pressure
Slow Heartbeat
Abnormally Low Blood Pressure
Fast Heartbeat

Rare side effects of atracurium IV:
Problems with Circulation
A Spasm of the Larynx
Bronchospasm
Inflammation of Skin caused by an Allergy
Redness of Skin
Itching
Hives
Rash
Visible Water Retention
Blood Circulation Failure due to Serious Heart Condition
Life Threatening Allergic Reaction

[#printed] => 1 ) [field_storage] => Array ( [#type_name] => product [#context] => full [#field_name] => field_storage [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 11 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_storage [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => • Store below 30 C° • Protect from light and freezing [format] => 1 [safe] =>

• Store below 30 C°
• Protect from light and freezing

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

• Store below 30 C°
• Protect from light and freezing

) [#title] => [#description] => [#children] =>

• Store below 30 C°
• Protect from light and freezing

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_storage [#title] => Storage [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

• Store below 30 C°
• Protect from light and freezing

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Storage: 

• Store below 30 C°
• Protect from light and freezing

[#printed] => 1 ) [field_packing] => Array ( [#type_name] => product [#context] => full [#field_name] => field_packing [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 12 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_packing [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => • Atracurium Injection 50mg/5ml:5 Ampoules/ Box [format] => 1 [safe] =>

• Atracurium Injection 50mg/5ml:5 Ampoules/ Box

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

• Atracurium Injection 50mg/5ml:5 Ampoules/ Box

) [#title] => [#description] => [#children] =>

• Atracurium Injection 50mg/5ml:5 Ampoules/ Box

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_packing [#title] => Packing [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

• Atracurium Injection 50mg/5ml:5 Ampoules/ Box

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Packing: 

• Atracurium Injection 50mg/5ml:5 Ampoules/ Box

[#printed] => 1 ) [field_references] => Array ( [#type_name] => product [#context] => full [#field_name] => field_references [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 13 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_references [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => [format] => [safe] => [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [#title] => [#description] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_references [#title] => References [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#printed] => 1 ) [#title] => [#description] => [#printed] => 1 ) [field_pdf] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pdf [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 14 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pdf [#weight] => 0 [#theme] => filefield_formatter_default [#item] => Array ( [fid] => 171 [uid] => 1 [filename] => atracurium.pdf [filepath] => sites/default/files/pdf/atracurium.pdf [filemime] => application/pdf [filesize] => 511067 [status] => 1 [timestamp] => 1329486214 [list] => 1 [data] => [i18nsync] => 1 [nid] => 279 [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] => ) [#title] => [#description] => [#children] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pdf [#title] => PDF [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] => [#printed] => 1 ) [#title] => [#description] => [#children] => [#printed] => 1 ) [field_related_products] => Array ( [#type_name] => product [#context] => full [#field_name] => field_related_products [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 15 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_related_products [#weight] => 0 [#theme] => nodereference_formatter_default [#item] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [1] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_related_products [#weight] => 1 [#theme] => nodereference_formatter_default [#item] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [#delta] => 1 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [2] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_related_products [#weight] => 2 [#theme] => nodereference_formatter_default [#item] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [#delta] => 2 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [#title] => [#description] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_related_products [#title] => Related Products [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#printed] => 1 ) [#title] => [#description] => [#printed] => 1 ) [#title] => [#description] => [#children] =>
Image: 
Brand Name: 

-

Dosage Form: 

Injection 50mg/5ml

Pharmacological Category: 

Nondepolarizing skeletal muscle relaxant

Therapeutic Category: 

Antimyasthenics, Muscle Relaxants

Pregnancy Category: 

C

Antagonize the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate

Pharmacokinetics: 

The ED95 has averaged 0.23 mg/kg (0.11 to 0.26 mg/kg in various studies). An initial atracurium dose of 0.4 to 0.5 mg/kg generally produces maximum neuromuscular block within 3 to 5 minutes of injection, with good or excellent intubation conditions within 2 to 2.5 minutes in most patients. Recovery from neuromuscular block (under balanced anesthesia) can be expected to begin approximately 20 to 35 minutes after injection. Under balanced anesthesia, recovery to 25% of control is achieved approximately 35 to 45 minutes after injection, and recovery is usually 95% complete approximately 60 to 70 minutes after injection. The neuromuscular blocking action of atracurium is enhanced in the presence of potent inhalation anesthetics. Isoflurane and enflurane increase the potency of atracurium and prolong neuromuscular block by approximately 35%; however, halothane’s potentiating effect (approximately 20%) is marginal.

After an initial dose of 0.4 to 0.5 mg/ maintenance dose (suggested maintenance dose is 0.08 kg under balanced anesthesia, the first to 0.10 mg/kg) is generally required within 20 to 45 minutes, and subsequent maintenance doses are usually required at approximately 15 to 25 minute intervals. The pharmacokinetics of atracurium in humans are essentially linear within the 0.3 to 0.6 mg/kg dose range. The elimination half-life is approximately 20 minutes. The duration of neuromuscular block produced by atracurium besylate does not correlate with plasma pseudocholinesterase levels and is not altered by the absence of renal function.

Indications: 

Adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Contraindications: 

• Patients known to have a hypersensitivity to it

Precautions: 

• Request information from your patients about previous anaphylactic reactions to other neuromuscular blocking agents.
• inform your patients that severe anaphylactic reactions to neuromuscular blocking agents, including atracurium besylate have been reported.

Drug Interactions: 

Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine.

If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered.

Side Effects: 

Common side effects of atracurium:
Temporary Redness of Face and Neck

Infrequent side effects of atracurium:
High Blood Pressure
Slow Heartbeat
Abnormally Low Blood Pressure
Fast Heartbeat

Rare side effects of atracurium IV:
Problems with Circulation
A Spasm of the Larynx
Bronchospasm
Inflammation of Skin caused by an Allergy
Redness of Skin
Itching
Hives
Rash
Visible Water Retention
Blood Circulation Failure due to Serious Heart Condition
Life Threatening Allergic Reaction

Storage: 

• Store below 30 C°
• Protect from light and freezing

Packing: 

• Atracurium Injection 50mg/5ml:5 Ampoules/ Box

[#printed] => 1 ) [links] => Array ( [node_translation_fa] => Array ( [title] => فارسی [href] => node/104 [language] => stdClass Object ( [language] => fa [name] => Persian [native] => فارسی [direction] => 1 [enabled] => 1 [plurals] => 0 [formula] => [domain] => [prefix] => fa [weight] => 3 [javascript] => ) [attributes] => Array ( [title] => آتراکوریوم بسیلات [class] => translation-link ) ) ) )
button

CONTACT US:

Head Office:
Address: No.1, Beastoon Ave., Dr. Fatemi Sq., Tehran1431663135 Iran
Tel: (+98 21)-889 65323
Fax: (+98 21)-889 57056
Factory:
Address: Caspian tamin Pharmaceutical Co., Entrance 1, Rasht Industrial Zone, Rasht, Guilan, Iran
Tel: (+98 131) 338-2511- 8
Fax: (+98 131) 338 – 2517